Sihuan Pharmaceutical Holdings Group (SZSC:460) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

460 Stoklara Genel Bakış

Bir yatırım holding şirketi olan Sihuan Pharmaceutical Holdings Group Ltd. Çin Halk Cumhuriyeti'nde farmasötik ve medikal estetik ürünlerin araştırma ve geliştirme, üretim, pazarlama ve satışını yapmaktadır.

Şirket hakkında

460 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	2/6

Ödüller

Kazançlar son 5 yılda yılda 13% oranında arttı

Risk Analizi

6.06% temettüsü kazançlar veya serbest nakit akışları tarafından iyi karşılanmıyor

Sihuan Pharmaceutical Holdings Group Ltd. Rakipler

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

SEHK:1349

HK$7.5b

Beijing Tong Ren Tang Chinese Medicine

SEHK:3613

HK$7.0b

Consun Pharmaceutical Group

SEHK:1681

HK$6.6b

Tong Ren Tang Technologies

SEHK:1666

HK$6.9b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Sihuan Pharmaceutical Holdings Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$0.71
52 Haftanın En Yüksek Seviyesi	HK$1.02
52 Haftanın En Düşük Seviyesi	HK$0.49
Beta	0.60
11 Aylık Değişim	31.48%
3 Aylık Değişim	26.79%
1 Yıllık Değişim	16.39%
33 Yıllık Değişim	-59.20%
5 Yıllık Değişim	-33.64%
Halka arzdan bu yana değişim	-66.19%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	460	HK Pharmaceuticals	HK Pazar
7D	-4.1%	-1.9%	-1.0%
1Y	16.4%	27.2%	20.3%

Getiri vs. Endüstri: 460 geçen yıl % 29.7 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: 460 geçen yıl % 20.3 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 460's price volatile compared to industry and market?
460 volatility
460 Average Weekly Movement	12.0%
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

İstikrarlı Hisse Senedi Fiyatı: 460 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 460 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2001	2,648	Weicheng Guo	www.sihuanpharm.com

Bir yatırım holding şirketi olan Sihuan Pharmaceutical Holdings Group Ltd., Çin Halk Cumhuriyeti'nde farmasötik ve medikal estetik ürünlerin araştırma ve geliştirme, üretim, pazarlama ve satışını yapmaktadır. Şirket üç segmentte faaliyet göstermektedir: Medikal Estetik Ürünler, Yenilikçi Tıp ve Diğer İlaçlar ve Jenerik İlaçlar. Dolgu, şekillendirme, destekleme, tamamlama, optoelektronik cihaz, vücut şekillendirme, cilt bakımı ve diğerlerinin yanı sıra non veya minimal invaziv medikal estetik kapsamlı çözümler sunmaktadır.

Sihuan Pharmaceutical Holdings Group Ltd. Temel Bilgiler Özeti

Sihuan Pharmaceutical Holdings Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
460 temel i̇stati̇sti̇kler
Piyasa değeri	HK$6.62b
Kazançlar(TTM)	-HK$41.36m
Gelir(TTM)	HK$1.92b

3.4x

P/S Oranı

-160.0x

F/K Oranı

460 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
460 gelir tablosu (TTM)
Gelir	CN¥1.75b
Gelir Maliyeti	CN¥598.10m
Brüt Kâr	CN¥1.16b
Diğer Giderler	CN¥1.19b
Kazançlar	-CN¥37.80m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.0041
Brüt Marj	65.91%
Net Kâr Marjı	-2.15%
Borç/Özkaynak Oranı	21.4%

460 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

5.8%

Mevcut Temettü Verimi

-467%

Ödeme Oranı

460 Stoklara Genel Bakış

Ödüller

Risk Analizi

Sihuan Pharmaceutical Holdings Group Ltd. Rakipler

SEHK:1349

HK$7.5b

SEHK:3613

HK$7.0b

SEHK:1681

HK$6.6b

SEHK:1666

HK$6.9b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Recent updates

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA

Now 21% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021